International pharmacopoeias lack harmonized quality standards for peptide drugs, creating barriers to global peptide therapeutic development despite growing industry interest.
Standards vary by countryDifferent international pharmacopoeias use different test methods and specifications for the same peptide drugs, creating unnecessary barriers to global market access
What the researchers found
The global regulatory landscape for peptide-based therapeutics (PbTs) suffers from a significant lack of harmonization. Different pharmacopoeias (the official standards books used by regulators in different countries) use different test methods, specifications, and quality standards for the same peptide drugs. This inconsistency creates barriers for the global pharmaceutical industry and could slow the adoption of new peptide therapeutics.
The review identifies peptides' core advantages — high selectivity, strong efficacy, and low toxicity — as driving increased industry investment. However, the authors argue that standardizing quality specifications and test methods across international pharmacopoeias would further accelerate peptide drug development and global market access.
Why it matters
The peptide therapeutics market has been growing rapidly, but regulatory complexity remains a major barrier. When different countries apply different quality standards to the same peptide drug, manufacturers face increased costs, delayed approvals, and market fragmentation. Harmonizing these standards would make it easier and cheaper to bring peptide drugs to patients worldwide — particularly important as the pipeline of peptide therapeutics continues to expand.
The numbers in context
Multiple pharmacopoeias compared · Lack of harmonization across test procedures identified · Peptide selectivity, efficacy, and minimal toxicity highlighted as advantages · Global pharmaceutical industry interest increasing
How the study worked
The authors conducted a comparative review of pharmacopoeial standards for peptide-based therapeutics across major international pharmacopoeias. They analyzed test procedures, specifications, and monographs to identify commonalities and differences, focusing on quality control methodologies for peptide active pharmaceutical ingredients.
Who was studied
Review of international pharmacopoeial standards for peptide drugs
What this study cannot tell us
This is a regulatory landscape review rather than a clinical study, so it doesn't assess therapeutic efficacy or safety. The analysis focuses on published pharmacopoeial standards and may not capture internal regulatory policies or recent updates. The review was published in 2019, and regulatory frameworks continue to evolve. Specific pharmacopoeial editions analyzed may have been updated since.
How to read the evidence
This is a thorough comparative review of regulatory standards published in a respected drug discovery journal. It provides valuable analysis of pharmacopoeial harmonization gaps, but as a regulatory landscape review rather than a clinical study, it doesn't directly evaluate drug efficacy or patient outcomes.
When this study was published
Published in 2019, the specific pharmacopoeial editions analyzed may have been updated. However, the fundamental challenge of international harmonization for peptide drug standards remains relevant and largely unresolved.
The bigger picture
The peptide therapeutics market is projected to grow substantially as new drugs like GLP-1 agonists, antimicrobial peptides, and peptide-drug conjugates advance through pipelines. Regulatory harmonization isn't just a bureaucratic issue — it directly affects how quickly these treatments reach patients globally. This review highlights a practical bottleneck that the pharmaceutical industry and regulators need to address as the peptide drug class matures.
Questions still open
- Have international regulatory bodies made progress on harmonizing peptide drug quality standards since this 2019 review?
- Do the quality specification differences between pharmacopoeias actually lead to measurable differences in peptide drug quality across markets?
- How should regulators adapt quality standards as new peptide modalities like stapled peptides and peptide-drug conjugates enter the market?
Common questions
Why do different countries have different quality standards for the same peptide drug?
Does this lack of harmonization actually affect patients?
Read the original research
Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects.
Drug discovery today, 24(1), 148-162
Citation
Rastogi, Shruti; Shukla, Shatrunajay; Kalaivani, M; Singh, Gyanendra Nath. (2019). Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects.. Drug discovery today, 24(1), 148-162. https://doi.org/10.1016/j.drudis.2018.10.002